3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
4
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
62
Cyclophosphamide
60
Radiotherapy
48
Doxorubicin
36
Filgrastim
26
Radiation
24
Irinotecan
24
fludarabine
23
Gemcitabine
23
Magnetic Resonance Spectroscopy
21
Imatinib Mesylate
19
Etoposide
18
pembrolizumab
16
Cisplatin
15
Carboplatin
15
Biopsy
15
Bevacizumab
15
Specimen Handling
14
fludarabine phosphate
12
Nivolumab
12
Leucovorin
12
Ipilimumab
12
Granulocyte Colony-Stimulating Factor
12
Chemotherapy, Adjuvant
12
pazopanib
11
Vincristine
11
Ifosfamide
11
Melphalan
10
Erlotinib Hydrochloride
10
Docetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Immunotherapy
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled